Prevention of oropharyngeal candidiasis

Prevention of oropharyngeal candidiasis refers to prophylactic intervention against opportunistic fungal infection of the oral cavity and pharyngeal mucosa, predominantly caused by *Candida albicans* This clinical strategy targets vulnerable populations at heightened risk for mucosal fungal overgrowth, including individuals with cellular immunodeficiencies such as HIV/AIDS, patients receiving cytotoxic chemotherapy, bone marrow or solid organ transplant recipients, and individuals using broad-sp...

Prevention of oropharyngeal candidiasis refers to prophylactic intervention against opportunistic fungal infection of the oral cavity and pharyngeal mucosa, predominantly caused by *Candida albicans* The clinical condition is pathophysiologically marked by the proliferation and mucosal tissue invasion of commensal *Candida* species following disruption of local epithelial defenses or systemic immunity, which characteristically produces painful erythematous mucosal surfaces, friable white pseudom...

This clinical strategy targets vulnerable populations at heightened risk for mucosal fungal overgrowth, including individuals with cellular immunodeficiencies such as HIV/AIDS, patients receiving cytotoxic chemotherapy, bone marrow or solid organ transplant recipients, and individuals using broad-spectrum antibiotics or inhaled corticosteroids

This clinical strategy targets vulnerable populations at heightened risk for mucosal fungal overgrowth, including individuals with cellular immunodeficiencies such as HIV/AIDS, patients receiving cytotoxic chemotherapy, bone marrow or solid organ transplant recipients, and individuals using broad-spectrum antibiotics or inhaled corticosteroids The clinical condition is pathophysiologically marked by the proliferation and mucosal tissue invasion of commensal *Candida* species following disruption...

This clinical strategy targets vulnerable populations at heightened risk for mucosal fungal overgrowth, including individuals with cellular immunodeficiencies such as HIV/AIDS, patients receiving cytotoxic chemotherapy, bone marrow or solid organ transplant recipients, and individuals using broad-spectrum antibiotics or inhaled corticosteroids

The clinical condition is pathophysiologically marked by the proliferation and mucosal tissue invasion of commensal *Candida* species following disruption of local epithelial defenses or systemic immunity, which characteristically produces painful erythematous mucosal surfaces, friable white pseudomembranous plaques, dysgeusia, and dysphagia Prophylaxis aims to maintain mucosal integrity and avert local progression to esophageal candidiasis or secondary invasive systemic fungal dissemination

Prophylaxis aims to maintain mucosal integrity and avert local progression to esophageal candidiasis or secondary invasive systemic fungal dissemination